Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Stopped early · Phase 1 · Has a placebo group
Conditions studied: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Phenoxodiol may help docetaxel work better by making tumor cells more sensitive to the drug. PURPOSE: This randomized phase I/II trial is studying the side effects of docetaxel when given together with either phenoxodiol or placebo and to see how well it works in treating patients with recurrent advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.
Key facts
- Study ID
- NCT00303888
- Run by
- Yale University
- People needed
- 31
- Starts
- 2006-05-01
- Expected to finish
- 2009-10-01
- Last updated by the study team
- 2018-01-17
Who can join
Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Yale Cancer Center — New Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.